Joint (NASDAQ:JYNT)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a research note issued on Friday. They presently have a $7.00 target price on the stock. Maxim Group’s target price indicates a potential upside of 29.87% from the company’s previous close.
The analysts wrote, “4Q17 revenue of $6.93M, up 19.9% y/y, was above both our estimate of $6.62M and consensus of $6.64M. System-wide comp sales grew 26% y/y. GAAP EPS of ($0.02) was slightly narrower than both our estimate and consensus of ($0.03). 2018 guidance issued with revenue bracketing our estimates and above consensus, but adjusted EBITDA below both our estimates and consensus. JYNT plans to open 40-50 franchise clinics, add up to 2 new corporate-owned clinics (greenfields), and purchase up to 3 existing franchises (buybacks).””
A number of other analysts also recently weighed in on the company. ValuEngine upgraded Joint from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research downgraded Joint from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $5.86.
Joint (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, March 8th. The company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. Joint had a negative return on equity of 66.65% and a negative net margin of 13.01%. The firm had revenue of $6.93 million for the quarter, compared to the consensus estimate of $6.48 million. equities research analysts predict that Joint will post 0.08 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of JYNT. Boston Partners boosted its stake in shares of Joint by 25.4% in the third quarter. Boston Partners now owns 189,200 shares of the company’s stock valued at $901,000 after buying an additional 38,300 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Joint by 28.4% in the third quarter. Russell Investments Group Ltd. now owns 112,900 shares of the company’s stock valued at $538,000 after buying an additional 25,000 shares in the last quarter. Skylands Capital LLC boosted its stake in shares of Joint by 11.0% in the fourth quarter. Skylands Capital LLC now owns 612,529 shares of the company’s stock valued at $3,038,000 after buying an additional 60,900 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Joint in the fourth quarter valued at approximately $379,000. Finally, Deutsche Bank AG boosted its stake in shares of Joint by 3,839.1% in the fourth quarter. Deutsche Bank AG now owns 59,087 shares of the company’s stock valued at $293,000 after buying an additional 57,587 shares in the last quarter. Hedge funds and other institutional investors own 49.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Joint (JYNT) Stock Rating Reaffirmed by Maxim Group” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3255169/joint-jynt-stock-rating-reaffirmed-by-maxim-group.html.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.